Skin is the largest and fastest-growing organ in the human body. There are over 3,000 different skin conditions and diseases which impact millions of people worldwide and can have significant, multidimensional effects on patients’ quality of life, including their physical, functional and emotional well-being. According to multiple published studies, patients report that dermatology conditions affect quality of life in ways comparable to other serious diseases, such as cancer, heart disease, diabetes, epilepsy, asthma and arthritis.
Dermira is focused on bringing innovative and differentiated products to dermatologists and their patients for the treatment of highly prevalent diseases such as psoriasis, atopic dermatitis, hyperhidrosis and acne. The medical dermatology market was valued at over $21 billion in global pharmaceutical sales in 2012.
We believe that an overall lack of innovation in the research and development of new dermatology products has resulted in a limited number of new treatment options, severely underserving dermatologists and their patients. For example, the three mechanisms of action most commonly used to treat acne have been available for over 30 years. However, the few truly innovative therapies launched over the past few decades have resulted in significant sales, as illustrated by the success of targeted, immune-modifying biologics for the treatment of moderate-to-severe plaque psoriasis. This new class of therapy, launched in 2002, created a global market of approximately $4.0 billion in 2012 sales and continues to grow.
Recent advances in the understanding of skin disease biology are creating significant new opportunities for innovative product development, as illustrated by the commercial success of these biologics. We believe that Dermira, as a company solely focused on dermatology, can accelerate the pace of innovation in this field and establish Dermira as a leader in dermatology product development and commercialization.
Source: VisionGain. “Dermatological Drugs Market Forecast 2014 – 2024. Prospects for Leading Companies”. 2014.